# Shanghai Yingli Pharmaceutical

Source: https://onco.cc/companies/shanghai-yingli/  
OnCo record `shanghai-yingli` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.

## Summary

Shanghai Yingli Pharmaceutical is a small-molecule company in Shanghai's Zhangjiang science park. Its PI3K-delta inhibitor linperlisib (YY-20394) received conditional NMPA approval in November 2022 for relapsed or refractory follicular lymphoma after two or more lines, and is in trials in peripheral T-cell lymphoma and solid tumours.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Yingli Pharma
- Tags: ctgov-sponsor; china
- HQ: Shanghai, China
- Type: biotech
- Website: https://www.yingli-pharma.com

## Sources

- Official website: https://www.yingli-pharma.com

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Linperlisib](https://onco.cc/drugs/linperlisib/)
- trials: [A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma](https://onco.cc/trials/nct04379167/), [YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06662669/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-yingli.json